Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pilsicainide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.97 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.46 |
| ▸ | SCN3A known ✓ | Q9NY46 | 3/20 | 0.43 |
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.43 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.43 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.43 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.43 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.43 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pilsicainide SCHEMBL483631 | 0.99 | KCNH2 (0.95) | KCNH2ATML3MBTL1POLBMAPT | |
| Pilsicainide SCHEMBL14471484 | 0.99 | KCNH2 (0.95) | KCNH2ATML3MBTL1POLBMAPT | |
| Pilsicainide SCHEMBL142244 | 0.99 | KCNH2 (1.00) | KCNH2ATML3MBTL1POLBMAPT | |
| Pilsicainide SCHEMBL14809244 | 0.99 | KCNH2 (1.00) | KCNH2ATML3MBTL1POLBMAPT | |
| Pilsicainide SCHEMBL1650876 | 0.96 | KCNH2 (0.95) | KCNH2ATML3MBTL1POLBMAPT | |
| SCHEMBL15551940 | 0.84 | KCNH2 (0.74) | KCNH2L3MBTL1POLBMAPTGAA | |
| SCHEMBL10840605 | 0.79 | KCNH2 (0.66) | KCNH2POLBLMNAKMT2AALDH1A1 | |
| SCHEMBL10371948 | 0.73 | KCNH2 (0.58) | KCNH2ATML3MBTL1POLBMAPT | |
| Pyrrocaine SCHEMBL10757216 | 0.73 | MEN1 (0.68) | KCNH2ATML3MBTL1POLBLMNA | |
| Pyrrocaine SCHEMBL25718 | 0.71 | MEN1 (0.70) | KCNH2ATML3MBTL1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150164871-A1 | Pharmaceutical Compositions for Combination Therapy | ACESION PHARMA (DK) | 2015-06-18 | — | — | US | claimed |
| EP-2861254-A2 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | Acesion Pharma ApS (DK) | 2015-04-22 | — | — | EP | claimed |
| WO-2013185764-A2 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | ACESION PHARMA (DK) | 2013-12-19 | — | — | WO | claimed |
| US-20070196504-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | claimed |
| US-20070148235-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | claimed |
| US-20050152975-A1 | Pharmaceutical composition | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-07-14 | — | — | US | claimed |
| US-20040022848-A1 | Medicinal composition | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-05 | — | — | US | claimed |
| EP-1319399-A1 | MEDICINAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-18 | — | — | EP | claimed |
| EP-1161956-A1 | MEDICINAL COMPOSITIONS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | claimed |
| US-20260144747-A1 | SYRUP PREPARATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-4606435-A2 | PHARMACEUTICAL COMPOSITION COMPRISING POORLY SOLUBLE BASIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-27 | — | — | EP | disclosed |
| EP-4316598-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY SOLUBLE BASIC AGENT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-20240401031-A1 | Platform Using iPSC-Derived Cardiomyocytes Carrying Gene Variants as Models of Cardiac Disease and Drug-Response | SRI INTERNATIONAL | 2024-12-05 | — | — | US | disclosed |
| EP-1161956-A1 | MEDICINAL COMPOSITIONS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | disclosed |
| EP-1138333-A1 | MEDICINAL COMPOSITIONS FOR ORAL USE | SUNTORY LIMITED (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6287596-B1 | DRUG DELIVERY | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-09-11 | — | — | US | disclosed |
| EP-1048300-A1 | DISINTEGRATING AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| EP-1020193-A1 | ORAL PREPARATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0922464-A1 | QUICKLY DISINTEGRABLE COMPRESSION-MOLDED MATERIALS AND PROCESS FOR PRODUCING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050152975-A1 | Pharmaceutical composition | TAS2R5, TAS2R60, TAS2R16 | KCNH2 1834/4885GAA 25/4885SCN3A 2879/4885 |
| US-20070148235-A1 | PHARMACEUTICAL COMPOSITION | TAS2R5, TAS2R60, TAS2R16 | KCNH2 1834/4885GAA 25/4885SCN3A 2879/4885 |
| US-12564594-B2 | Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile | KCNN2, KCNN1, KIT | KCNH2 739/4885GAA 2470/4885SCN3A 862/4885 |
| US-20040022848-A1 | Medicinal composition | CD44, CMA1, ACLY | KCNH2 1971/4885GAA 50/4885SCN3A 814/4885 |
| US-20260144747-A1 | SYRUP PREPARATION | ALK, IRAK1, IRAK3 | KCNH2 2235/4885GAA 4213/4885SCN3A 552/4885 |
| US-20070196504-A1 | PHARMACEUTICAL COMPOSITION | CMA1, HRH2, ACLY | KCNH2 2088/4885GAA 89/4885SCN3A 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.